Cancer Institute and Hospital, Chinese Academy of Medical Sciences: Carcinoma, Hepatocellular trials

The registry lists 15 Carcinoma, Hepatocellular studies with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor. 7 are open to participants now and 1 have results posted.

Phase 1 1Phase 2 10Phase 3 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular CarcinomaNot yet recruitingNCT07749859Phase 2
• A Phase I Study of CREPT-618 in Locally Advanced HCCRecruitingNCT07364357Phase 1
• Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular CarcinamoRecruitingNCT07239245Phase 2
• Adjuvant Radiotherapy of Sintilimab Versus TACE for HCCRecruitingNCT07186621Phase 3
• Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and Prognosis of TACE Combined With Targeted Immunotherapy in Unresectable Hepatocellular CarcinomaEnrolling by invitationNCT06540508
• Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor ThrombosisRecruitingNCT06389422Phase 2
• Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.RecruitingNCT06205472Phase 2
• Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical ResectionCompletedNCT03575806Phase 2Results posted
• Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor ThrombosisCompletedNCT06233981Phase 2
• SBRT With DIBH for HCC After TACE and Lipiodol MarkingActive, not recruitingNCT05021250Not applicable
• A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and OxaliplatinStatus unknownNCT04850040Phase 2
• Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCCCompletedNCT04791176Phase 2
• Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma with PVTTTerminatedNCT04709380Phase 3
• Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical ResectionStatus unknownNCT03839550Phase 2
• Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular CarcinomaCompletedNCT03535259Phase 2